Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value Catalysts

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Mental health disorders—including depression, anxiety, PTSD, and bipolar disorder—continue to represent one of the largest and fastest-growing areas of unmet medical need worldwide. The global mental health therapeutics market is projected to surpass $40 billion over the next several years, supported by increased diagnosis rates, broader insurance coverage, and reduced stigma around seeking care.

Why it matters

The global opportunity for depression and anxiety treatments alone is estimated to exceed $50–60 billion annually, and the broader neuropsychiatric drug market is projected to surpass $150 billion by the end of the decade. As awareness and acceptance of new serotonin-based therapies increase, NSAs are positioned to capture a meaningful slice of this spend—especially if clinical data continues to show rapid symptom relief and improved patient outcomes.

The details

Helus Pharma, a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, has appointed Dr. Freda Lewis-Hall, a pioneering physician and biopharmaceutical executive with more than 40 years of experience, to its Board of Directors and as Chair of the Scientific Advisory Committee. Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio.

  • Helus Pharma announced the appointment of Dr. Freda Lewis-Hall on February 24, 2026.

The players

Helus Pharma

A clinical stage pharmaceutical company developing novel serotonergic agonists (NSAs) for serious mental health conditions.

Dr. Freda Lewis-Hall

A pioneering physician and biopharmaceutical executive with more than 40 years of experience spanning clinical care, research, academia, corporate leadership, and public health advocacy.

Got photos? Submit your photos here. ›

What they’re saying

“Dr. Lewis-Hall is a highly respected physician and leader whose career has been defined by bringing complex, innovative therapies from development to patients around the world, particularly in areas of serious and underserved mental health need. Her deep experience in clinical strategy, regulatory engagement, and global commercialization will be invaluable as we advance our novel serotonergic agonist programs for psychiatric disorders and continue building a company grounded in scientific rigor, patient impact, and responsible scale. We are honored to welcome her to our Board and as Chair overseeing the Scientific Advisory Committee.”

— Michael Cola, Chief Executive Officer of Helus Pharma

“Throughout my career, I have focused on ensuring that scientific innovation translates into therapies that make a meaningful difference for patients — and that can be delivered reliably within real-world healthcare systems. What distinguishes Helus Pharma is its disciplined approach at the intersection of rigorous science, a thoughtfully advancing clinical portfolio, and focused execution in areas of significant unmet need in mental health. I believe the company is building a differentiated development platform that has yet to be fully recognized by the broader market.”

— Dr. Freda Lewis-Hall

The takeaway

The appointment of Dr. Freda Lewis-Hall, a highly respected physician and biopharmaceutical executive, to Helus Pharma's Board of Directors and as Chair of the Scientific Advisory Committee underscores the company's commitment to advancing its novel serotonergic agonist (NSA) portfolio for serious mental health conditions. Her deep expertise in clinical strategy, regulatory engagement, and global commercialization will be invaluable as Helus Pharma aims to capitalize on the growing $40 billion-plus market opportunity in the mental health therapeutics space.